Skip to main content
Valiant Laboratories Limited logo

Valiant Laboratories Limited — Investor Relations & Filings

Ticker · VALIANTLAB ISIN · INE0JWS01017 LEI · 335800VKNJKWJ4LD6855 BSE.NS Manufacturing
Open in API
Filings indexed 171 across all filing types
Latest filing 2025-09-30 Regulatory Filings
Country IN India
Listing BSE.NS VALIANTLAB

About Valiant Laboratories Limited

https://www.valiantlabs.in/

Valiant Laboratories Limited specializes in the manufacturing of Active Pharmaceutical Ingredients (APIs) and bulk drugs, with a primary focus on the production of Paracetamol. The company operates dedicated manufacturing facilities designed for the large-scale synthesis of analgesic and antipyretic compounds. By maintaining rigorous quality control standards and process efficiencies, it serves as a key supplier for formulations across various therapeutic segments. Its core business activities encompass the chemical processing and distribution of high-grade medicinal ingredients, catering to a diverse range of healthcare manufacturers. The organization prioritizes technical excellence in API synthesis and the optimization of production workflows to ensure a consistent supply of essential pharmaceutical components.

Recent filings

Filing Released Lang Actions
Pendency of Litigation(s)/dispute(s) or the outcome impacting the Company
Regulatory Filings Classification · 95% confidence The document is an intimation under Regulation 30 of the SEBI Listing Obligations and Disclosure Requirements Regulations, 2015. It discloses receipt of a Show-Cause Notice from a tax authority regarding alleged wrong availment of Input Tax Credit and potential financial implications. The document is a regulatory announcement about a legal proceeding or regulatory action, not a full legal proceeding report or audit report. It is a compliance disclosure to stock exchanges and investors about a material event. The document length is 3909 characters, which is relatively short and consistent with a regulatory filing or announcement. There is no detailed financial data or comprehensive report content. Therefore, the best fitting category is Regulatory Filings (RNS), which covers general regulatory announcements and compliance disclosures that do not fit other specific categories.
2025-09-30 English
Trading Window
Regulatory Filings Classification · 95% confidence The document is a formal letter addressed to stock exchanges informing about the closure of the trading window for insiders ahead of the financial results announcement for the quarter and half year ended September 30, 2025. It references compliance with SEBI (Prohibition of Insider Trading) Regulations and the company's code of conduct. The document is short (1680 characters) and serves as a regulatory announcement related to insider trading restrictions, not a financial report or earnings release itself. It does not contain financial data or results but is a compliance notification. Therefore, it fits best under Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other categories.
2025-09-29 English
Shareholders meeting
Regulatory Filings
2025-09-26 English
Change in Management
Board/Management Information Classification · 95% confidence The document is a formal communication addressed to stock exchanges (BSE and NSE) regarding changes in the company's management. It references Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, which pertains to disclosures about changes in directors or key managerial personnel. The content includes re-appointment of a director, change in designation of an executive, and appointment of secretarial auditors, with detailed profiles and terms of appointment. There is no financial data or report analysis, but rather an announcement of management changes. This fits the category of Board/Management Information (MANG). The document length (7416 characters) supports it being a detailed announcement rather than a brief notice or a full report like an annual or interim report.
2025-09-25 English
Shareholders meeting
AGM Information Classification · 100% confidence The document is titled 'Proceedings of the 4th Annual General Meeting' and details the events and resolutions transacted during the AGM held on September 25, 2025. It includes attendance, presentations by the Managing Director, resolutions passed, shareholder interactions, and voting procedures. The document explicitly states it is a summary of the AGM proceedings and not the minutes. It does not contain full financial statements or detailed financial performance data, but rather a summary of the meeting's conduct and decisions. This matches the definition of AGM Information (AGM-R), which covers presentations and materials shared during the Annual General Meeting. The document length (8826 characters) is sufficient to be a full summary rather than a brief announcement. Therefore, the correct classification is AGM Information (AGM-R).
2025-09-25 English
Copy of Newspaper Publication
Regulatory Filings
2025-09-03 English

Browse filings by year

4 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.